Reaction: the Google Books ruling

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Reaction: the Google Books ruling

Google Books 100

Following the Second Circuit ruling that Google’s book scanning project is fair use, observers are divided on the merits of a Supreme Court appeal from The Authors Guild



Google Books

In a unanimous decision, the Second Circuit on October 16 ruled that Google Books’ scanning and indexing of books is a transformative use that renders a public benefit, leading to a finding of fair use.

This is the latest development in a decade-long saga that, as the Second Circuit noted in its opinion, tests the boundaries of fair use. The Court found that all four statutory factors favored finding fair use, in large part because of the highly transformative nature of Google Books and the low risk that it would act as a market substitute for the original works. The Court also rejected the rest of the plaintiffs’ arguments, including that Google infringed their exclusive right to apply search and snippet views to their own works and that Google contributed to infringement by libraries participating in the program.

The Authors Guild in a statement slammed the decision as a “reductive understanding of fair use” and said it will appeal to the Supreme Court.

Michael Keyes, an intellectual property partner at the international law firm Dorsey & Whitney, said the immediate effect of the ruling is that Google will be able to continue its large-scale book scanning project in its present form without fear of copyright liability.

But he added: “I think the long-term effects could be significant. It could open the door for other similar types of digitization projects involving copyrighted works so that those works could be catalogued and searched.”

Joshua Schiller, partner at Boies Schiller & Flexner, doubts an appeal to the Supreme Court would be successful. “It is unlikely that the Supreme Court will take a petition, if one is filed, since this case keeps consistent the law of fair use among the circuits.”

Others, however, believe there are issues to be debated at the Supreme Court regarding this case. David Leichtman, a partner at Robins Kaplan, commented: “[The] decision is also at odds with both the 7th Circuit and the 11th Circuit, and thus now sets up a showdown in the Supreme Court over what it meant in 1994 when it used the word ‘transformative’ in the fair use context.”



more from across site and SHARED ros bottom lb

More from across our site

Evan Lazerowitz, attorney in Robinson + Cole’s bankruptcy and reorganisation group, offers key takeaways for IP interested parties in bankruptcy and insolvency proceedings
While the UK sees heavy IP rankings movement, Germany’s new tiered UPC table signals a shift from early adoption to market maturity
In an exclusive interview, Bernard Ledeboer reveals how a Consolid-backed group of firms wants to expand across Europe, invest in AI and centralise operations to compete at the top tier
Not all private equity firms are the same, so leaders at four externally backed IP firms came together to discuss the frameworks they followed and how they ensured a cultural fit
Top-tier German and Spanish firms are among the advisers on a Europe-wide copyright and licensing tussle concerning the design of the track circuit in Madrid
Partners Alex Wilson and Andreas Kramer say bigger law firm rivals don’t necessarily gain by having a wider jurisdictional reach
VO, which has offices in the Netherlands, Belgium and Germany, is the second European IP firm to secure external backing this week
The Bardehle Pagenberg attorneys-at-law discuss the firm’s Managing IP EMEA Awards 2026 success, Unified Patent Court litigation strategy, and evolving European patent trends
A patent battle between two legal tech companies and a loss for Elon Musk’s xAI against OpenAI were also among the top talking points
With drug prices a hot topic in the US, courts are seemingly more reluctant to prevent the entry of generics to the market
Gift this article